Publications by authors named "Karim Safer"
Article Synopsis
- The study focused on a bispecific antibody, JNJ-67571244, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), aiming to identify maximum tolerated dose and safety outcomes.
- The phase I trial, involving 68 patients, encountered significant side effects and toxicity, with 88.2% showing treatment-emergent adverse events, while no substantial clinical responses were observed.
- The prolonged treatment strategy intended to enhance tolerability did not prevent adverse effects, and the study was terminated without achieving the planned exposure levels for determining effective dosing.
Background: Interleukin-6 (IL-6) is associated with prostate cancer morbidity. In several experimental models, IL-6 has been reported to have anti-apoptotic and pro-angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti-IL-6 antibody which has been successfully applied in several models representing prostate cancer.
View Article and Find Full Text PDFDetermining the mechanism of Ag loading of Langerhans cells (LC) for genetic immunization (GI) is complicated by the inability to distinguish between the response generated by direct transfection of LC from that due to exogenous uptake. To unravel this mechanism, we examined the impact of gene gun treatment on LC with respect to their activation and migration from skin, transgene expression, and ability to initiate humoral and cellular immune responses upon transfer to naive mice. To assess responses generated by direct LC transfection, an RU486-inducible expression system was used as a GI vector.
View Article and Find Full Text PDF